279 related articles for article (PubMed ID: 37513579)
1. Phosphate Control in Peritoneal Dialysis Patients: Issues, Solutions, and Open Questions.
Cernaro V; Calderone M; Gembillo G; Calabrese V; Casuscelli C; Lo Re C; Longhitano E; Santoro D
Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513579
[TBL] [Abstract][Full Text] [Related]
2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
[TBL] [Abstract][Full Text] [Related]
4. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis.
Bernardo AP; Contesse SA; Bajo MA; Rodrigues A; Del Peso G; Ossorio M; Cabrita A; Selgas R
Clin J Am Soc Nephrol; 2011 Mar; 6(3):591-7. PubMed ID: 21115631
[TBL] [Abstract][Full Text] [Related]
6. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
Locatelli F; Del Vecchio L; Violo L; Pontoriero G
Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
[TBL] [Abstract][Full Text] [Related]
7. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
Ureña Torres PA
Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
[TBL] [Abstract][Full Text] [Related]
8. Phosphate Binders and Targets Over Decades: Do We have it Right Now?
Marcuccilli M; Chonchol M; Jovanovich A
Semin Dial; 2017 Mar; 30(2):134-141. PubMed ID: 28064444
[TBL] [Abstract][Full Text] [Related]
9. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal phosphate removal varies by peritoneal dialysis regimen: an underestimated parameter of phosphate control.
Botelho C; Rodrigues A; Oliveira JC; Cabrita A
J Nephrol; 2013; 26(1):183-90. PubMed ID: 22460184
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Floege J
J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
[TBL] [Abstract][Full Text] [Related]
13. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
[TBL] [Abstract][Full Text] [Related]
14. Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand.
Tiong MK; Ullah S; McDonald SP; Tan SJ; Lioufas NM; Roberts MA; Toussaint ND
Nephrology (Carlton); 2021 Oct; 26(10):814-823. PubMed ID: 34046973
[TBL] [Abstract][Full Text] [Related]
15. Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription.
Courivaud C; Davenport A
Perit Dial Int; 2016; 36(1):85-93. PubMed ID: 26224788
[TBL] [Abstract][Full Text] [Related]
16. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
17. Contemporary management of phosphorus retention in chronic kidney disease: a review.
Amiri FS
Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
[TBL] [Abstract][Full Text] [Related]
18. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis.
Kuhlmann MK
Blood Purif; 2010; 29(2):137-44. PubMed ID: 20093819
[TBL] [Abstract][Full Text] [Related]
19. Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis.
Jiang N; Fang W; Gu AP; Yuan JZ; Yang XX; Lin AW; Ni ZH; Qian JQ
Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):846-852. PubMed ID: 26141941
[TBL] [Abstract][Full Text] [Related]
20. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
Brauer A; Waheed S; Singh T; Maursetter L
J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
